綠葉製藥(02186.HK)向MOKSHA8授予思瑞康®巴西及墨西哥獨家推廣權
格隆匯5月13日丨綠葉製藥(02186.HK)宣佈,集團全資子公司Luye Hong Kong與Moksha8的兩家子公司Moksha8 Brasil Distribuidora e Representação deMedicamentos Ltda.和Moksha8 Farmacéutica, S. de R.L . de C.V.,簽署了就思瑞康®和思瑞康緩釋片®在巴西及墨西哥的獨家推廣協議。
思瑞康®(富馬酸喹硫平、速釋、IR)及思瑞康緩釋片®(緩釋製劑)乃具有抗抑鬱特性的非典型抗精神病(AAP)藥物。思瑞康®的主要病症是治療精神分裂症和躁鬱症。思瑞康緩釋片®在若干市場亦獲准用於抑鬱症和廣泛性焦慮症。
巴西和墨西哥是拉丁美洲最大的兩個醫藥市場,合共佔有該地區70%的市場份額,並於2019年分別保持了9.3%和8.4%的同比增長率。根據IQVIA的預測,拉丁美洲醫藥行業將於2018至2023年達到7%的年複合增長率(CAGR)。
據悉,Moksha8是一家專科醫藥公司,聚焦於在拉丁美洲兩大醫藥市場—巴西和墨西哥引進、推廣和分銷創新及成熟藥品。
公司指,除思瑞康®系列產品外,集團還有多箇中樞神經系統在研項目,同步在中國及海外市場進行開發,其中在臨牀研究階段的項目包括LY03004(用於精神分裂和雙相情感障礙症)LY03003(用於帕金森病)、LY03005(用於抑鬱症)、LY03010(用於精神分裂症和分裂情感性障礙的治療)、LY30410(用於中輕度阿茲海默症)和LY03012(用於慢性疼痛)等。上述在研產品在中國、美國、歐洲和日本等戰略市場註冊進展良好,未來計劃在這些國家上市並進一步擴展到全球市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.